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Abstract
We present an optimized triple modality reporter construct combining a far-red fluorescent protein (E2-Crimson), enhanced
firefly luciferase enzyme (Luc2), and truncated wild type herpes simplex virus I thymidine kinase (wttk) that allows for
sensitive, long-term tracking of tumor growth in vivo by fluorescence, bioluminescence, and positron emission tomography.
Two human cancer cell lines (MDA-MB-231 breast cancer and HT-1080 fibrosarcoma cancer) were successfully transduced to
express this triple modality reporter. Fluorescence and bioluminescence imaging of the triple modality reporter were used
to accurately quantify the therapeutic responses of MDA-MB-231 tumors to the chemotherapeutic agent monomethyl
auristatin E in vivo in athymic nude mice. Positive correlation was observed between the fluorescence and bioluminescence
signals, and these signals were also positively correlated with the ex vivo tumor weights. This is the first reported use of both
fluorescence and bioluminescence signals from a multi-modality reporter construct to measure drug efficacy in vivo.
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Introduction
The development of noninvasive imaging technologies has
significantly advanced the field of molecular imaging. Molecular
imaging is commonly used to analyze cancer initiation and cancer
growth pathways as well as therapeutic responses in living subjects
[1]. However, each molecular imaging modality has strengths and
weaknesses. We combined a fluorescent protein gene for
fluorescence imaging, a luciferase gene for bioluminescence
imaging, and a thymidine kinase gene for positron emission
tomography (PET) scanning into a triple modality reporter
construct, wherein the three components offer complementary
advantages that compensate for the disadvantages of each
individual component.
The first component of our optimized triple reporter construct is
the far-red fluorescent protein E2-Crimson (excitation maximum
611 nm, emission maximum 646 nm) for fluorescence imaging.
Fluorescent proteins can be detected at single cell resolution
without requiring the administration of an exogenous substrate. As
a result, fluorescent proteins are useful for fluorescent-activated
cell sorting (FACS), determining transduction efficiency by
microscopy, tumor imaging during fluorescence-guided surgery,
and tumor identification and quantification in tissue sections.
Previous triple reporter designs have contained the shorter
wavelength EGFP (enhanced green fluorescent protein; excitation
maximum 488 nm, emission maximum 507 nm) or mRFP1
(monomeric red fluorescent protein; excitation maximum
584 nm, emission maximum 607 nm) [2–5]. However, short
wavelength fluorescence signal has greater attenuation in mam-
malian tissue due to the spectral overlap with heme absorbance in
vivo. Also, mRFP1 was an early monomeric red fluorescent
protein, which has been rendered completely obsolete. For this
reason, we chose an up-to-date far-red to infrared fluorescent
protein to allow for increased penetration of the fluorescence
signal in whole animal live imaging. However, several varieties of
such proteins existed, so we conducted an unbiased comparison of
the cellular expression and in vivo signals of E2-Crimson, infrared
fluorescent protein (IFP1.4), mNeptune, and mPlum.
The second gene in this triple reporter is enhanced firefly
luciferase (Luc2). Luc2 is a codon-optimized luciferase gene that
was engineered to have increased expression in mammalian cells.
Luc2 reportedly can detect single cancer cells in vivo by
bioluminescence [6], which is a higher sensitivity than reported
for firefly luciferase, Renilla luciferase, and mutant thermostable
firefly luciferase, all of which have been used in other triple
reporter constructs [2–5]. Unlike fluorescent proteins, Luc2
requires the external substrate D-luciferin and adenosine triphos-
phate (ATP) from living cells for the reaction that generates
photons of light visible as bioluminescence. Bioluminescence
imaging has superior signal-to-background ratios compared
to fluorescence imaging due to the absence of significant
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autoluminescence in mammalian tissues [7]. This superior signal-
to-background ratio with bioluminescence allowed for greater
sensitivity of imaging, as assessed by a lower number of cells
required for in vivo tumor detection with bioluminescence
compared to fluorescence in the triple reporter.
The third reporter gene in this triple reporter construct is
truncated wild type herpes simplex virus I thymidine kinase (wttk),
which is used for PET imaging. PET imaging, which is the only
method that is routinely used clinically, produces signal with the
best depth penetration compared to fluorescence and biolumines-
cence, and permits accurate three-dimensional reconstruction.
However, PET has low cellular resolution and sensitivity; thus,
PET quantification is less reliable in small tumors in mice.
Additionally, wttk requires the administration of the radiolabelled
probe 9-(4-18F-fluoro-3-[hydroxymethyl]butyl)guanine, referred to
as 18F-FHBG, to produce signal. Wttk phosphorylates 18F-FHBG
by transferring a phosphate group from ATP, which traps 18F-
FHBG in cells expressing wttk, allowing for PET imaging of wttk-
expressing tumors [8].
Previous triple reporter constructs have consisted of large fusion
proteins or contained internal ribosomal entry sites (IRES) [2–5]
to facilitate the co-expression of the three reporter genes. Large
fusions of all three reporter proteins can affect protein folding
and/or trafficking as well as reduce protein activity [5,9]. Also,
IRES-dependent gene expression is often significantly less efficient
than the 59 cap-dependent promoter-driven expression of the
preceding gene [10]. Instead, we used ‘self-cleaving’ viral 2A
sequences from porcine teschovirus-1 (P2A) and Thosea asigna virus
(T2A), where translational disruption between the glycine and
proline residues in the D-X-E-X-N-P-GQP consensus sequence
yields expression of separate proteins from a single multicistronic
mRNA. The 2A sequence-mediated ribosomal ‘skip’ allows for
efficient expression of multiple genes irrespective of their order in
the construct [11]. All three proteins should be transcribed at
equimolar amounts, though their steady-state levels will vary
according to their individual degradation rates. A Gly-Ser-Gly
linker precedes both 2A sequences for optimal cleavage [12].
Our optimized triple reporter was expressed and validated in
vitro and in vivo, in HEK293A human embryonic kidney, MDA-
MB-231 human breast cancer, and HT-1080 human fibrosarcoma
cell lines. Finally, we were able to accurately assess the therapeutic
responses of the MDA-MB-231 human breast cancer cell line
expressing the triple reporter in vivo to the chemotherapeutic
agents monomethyl auristatin E and F (MMAE and MMAF) with
fluorescence and bioluminescence imaging.
Results
Fluorescent proteins used in previously published triple report-
ers have been excited below 600 nm, overlapping with heme
absorbance, which contributes to depth attenuation. Because E2-
Crimson [13] (excitation maximum 611 nm), infrared fluorescent
protein [14] (IFP, excitation maximum 684 nm), mNeptune [15]
(excitation maximum 600 nm), and mPlum [16] (excitation
maximum 590 nm) have all been published separately, the
expression of these far-red to infrared FPs in stably transfected
cells has not been compared head-to-head in vivo. Stable,
consistent, and high expression of these proteins is necessary for
in vivo tumor imaging where fluorescent signal is monitored for
weeks to months of tumors growth. Comparing human fibrosar-
coma HT-1080 cells stably expressing E2-Crimson, IFP, mNep-
tune, or mPlum, HT-1080 E2-Crimson cells had the highest mean
quartile (mean 25% of cells) fluorescence according to fluorescent-
activated cell sorting (FACS) analysis, even though the far-red
settings were optimized for mPlum (ex 568 nm and em 650-
670 nm; IFP was assessed at ex 690 nm and em 710–900 nm)
(Figure 1A). The same was true for HT-1080 tumors in vivo, in
which HT-1080 E2-Crimson tumors had the highest in vivo
fluorescence at the far-red imaging settings (ex 590/23 nm and em
645LP for E2-Crimson, mNeptune, and mPlum; ex 640/48 nm
and em 700LP for IFP) (Figure 1B). E2-Crimson may be brighter
in vitro and in vivo from the combination of its high quantum yield,
tetrameric structure, and rapid folding stability. As a result, E2-
Crimson was incorporated into our optimized triple modality
reporter design.
The autofluorescence of tissues at excitation wavelengths shorter
than heme absorbance has contributed to inferior sensitivity of
shorter wavelength fluorescent proteins in vivo compared to
bioluminescence imaging [7]. Therefore, we hypothesized that
the longer wavelength E2-Crimson would have less competition
from autofluorescence and may have comparable sensitivity to
bioluminescence imaging. We evaluated the in vivo detection limits
of E2-Crimson and Luc2 in HT-1080 cells stably expressing the
triple reporter (Figure 2A) and found that fluorescence imaging
could be used to detect as few as 2,500 cells while bioluminescent
imaging could be used to detect as few as 500 cells (Figure S1).
For subsequent experiments, lentivirus containing the optimized
triple reporter construct (Figure 2A) was used to transduce the
MDA-MB-231 human breast cancer and HT-1080 human
fibrosarcoma cell lines. Three weeks after transduction, popula-
tions of stable cells from the cell lines were selected by FACS for
the brightest 1.5% of cells based on E2-Crimson fluorescence.
When imaged under the microscope at single cell level,
fluorescence was detected for .95% of cells in the field of view
(Figure 2B). Although cells were selected based on fluorescence
signal only, Luc2 and wttk were active in the stable cells as assayed
with bioluminescence and a ganciclovir toxicity assay, respectively
(Figure 2C and D).
We confirmed the complete self-cleavage of the viral 2A
sequences by Western blot analysis. While individual reporter
proteins were clearly detected in both triple reporter cell lines, we
did not detect any fusion protein consisting of all three modalities
(,135 kDa) or two of the successive modalities (,95 and
,106 kDa for E2-Crimson+Luc2 and Luc2+wttk, respectively)
(Figure 2E).
In vivo validation of the triple reporter imaging
modalities
Next, the expression of each modality was quantified in vivo
(Figure 3). Athymic nude mice (female, 6-weeks-old) were injected
bilaterally with MDA-MB-231 (16106 cells/tumor; orthotopic
into mammary fat pads) or HT-1080 (56105 cells/tumor;
subcutaneous at shoulder blades) cells that had been previously
transduced with the triple reporter. For each cell line imaged, eight
triple reporter and four untransduced tumors were generated.
There were no significant changes in the growth rate observed
between the tumors expressing the triple reporter and their
respective untransduced tumors.
All eight MDA-MB-231 triple reporter tumors, ranging from
45.2 to 238.8 mm3 based on positron emission tomography–
computed tomography (PET-CT) measurements, were healthy
and quantifiable by all three modalities. Two HT-1080 triple
reporter tumors, which were 446.5 and 520.4 mm3 based on PET-
CT measurements, were quantifiable by all three modalities
(Table 1).
One additional HT-1080 triple reporter tumor, measured to be
552.3 mm3 by PET-CT, was quantifiable by all three modalities.
However, this larger HT-1080 triple reporter tumor was excluded
Triple Reporter for Tumor Imaging and Therapy Evaluation
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from the data set summarized in Table 1 because it was the only
necrotic tumor generated in this study. The dead cells in this
tumor were visible by fluorescence, which is likely because stable
fluorescent proteins can remain visible in dead cells and debris
until they are proteolyzed, but they were not visible by
bioluminescence or PET, modalities that require ATP to generate
a signal.
The remaining five HT-1080 triple reporter tumors, ranging
from ,18 to 245 mm3 based on caliper measurements, were
quantifiable by fluorescence and bioluminescence signals but were
too small to detect by PET signal, so they were also excluded from
the data set summarized in Table 1 (Table S1). Despite their
significantly larger size, the average total PET signal (% injected
dose) of the HT-1080 triple reporter tumors successfully imaged by
all three modalities was not significantly higher than that of the
MDA-MB-231 triple reporter tumors (Table 1). The MDA-MB-
231 triple reporter cell line was chosen for use in the MMAE and
MMAF therapy experiment because this cell line showed more
uniform growth in vivo than the HT-1080 triple reporter cell line.
Furthermore, because the PET measurements of small murine
tumors were significantly less sensitive than fluorescence and
bioluminescence signals (tumors visible by fluorescence and
bioluminescence were not always visible by PET), PET was not
used to track the tumor therapeutic responses to MMAE.
Use of the triple reporter to monitor the response of sub-
palpable tumors to therapy
For the therapy experiment, MDA-MB-231 triple reporter cells
(7.56105) were implanted orthotopically into bilateral mammary
fat pads of athymic nude mice (female, 5-weeks-old). On day seven
post implantation, mice were randomized into three treatment
groups (untreated, MMAE-treated, and MMAF-treated, n= 5
mice per group). At this point, tumors were too small to be reliably
measured by calipers, but they had reliable fluorescence and
bioluminescence signals. We did not measure PET signal, as
tumors were smaller than the likely detection limit by PET for
tumor imaging in mice. Mice in the MMAE-treated and MMAF-
treated groups were treated every three days for a total of six doses
of 0.5 nmol/g starting on day seven. We did not expect a
therapeutic effect from MMAF treatment, as a charged phenyl-
alanine residue on the C-terminus of MMAF interferes with its
intracellular access [17].
On day 16, a significant decrease in the tumor fluorescence
signal (Figure 4A) was detected in the MMAE-treated group
(1.2610868.26107 [(p/s)/(cm2/sr)]) compared to the untreated
(3.4610861.16108 [(p/s)/(cm2/sr)]) and MMAF-treated (3.761086
1.46108 [(p/s)/(cm2/sr)]) groups (p=5.061024). On day 19, a
significant decrease in the tumor bioluminescence signal (Figure 4B)
was detected in the MMAE-treated group (1.7610861.36108 (p/s))
compared to the untreated (1.0610965.06108 (p/s)) and MMAF-
treated (8.0610864.76108 (p/s)) groups (p=2.061024). At no point
did the MMAF-treated group show a significant decrease in the
tumor fluorescence or bioluminescence signal compared to the
untreated group.
On day 16, tumors in the untreated and MMAF-treated groups
reached an average size of ,100 mm3. From then on, a caliper
was used to track therapy in addition to the fluorescence and
bioluminescence signals in the untreated and MMAF-treated
groups. Tumors in the MMAE-treated group remained smaller
than an average of ,100 mm3 throughout the experiment.
Caliper measurements were only attempted for tumors in the
MMAE-treated group on days 16 and 19 because of the small sizes
of the tumors due to treatment (Figure 4C). For both the untreated
and MMAF-treated groups, there was a strong correlation (on
days 16–28) between the fluorescence signal and caliper measure-
ments as well as between the bioluminescence signal and caliper
measurements (R2.0.83 for all cases, data not shown).
Four weeks post-implantation, the tumors were harvested and
weighed. The final in vivo fluorescence and bioluminescence signals
of the tumors directly correlated with each other (Figure 5A,
R2= 0.70) as well as with the ex vivo weights of the tumors (weight
vs. fluorescence signal: Figure 5B, R2= 0.74; weight vs. biolumi-
nescence signal: Figure 5C, R2= 0.62; Table 2).
Discussion
We report the successful generation of an optimized triple
modality reporter (Figure 2A) and viral transduction of this triple
reporter construct into two human cancer cell lines, MDA-MB-
231 and HT-1080. Both transduced cell lines expressed all three
modalities in vitro (Figure 2B–E) and in vivo (Figure 3). This triple
reporter construct was successfully used to quantify the therapeutic
responses of MDA-MB-231 human breast cancer tumors to the
chemotherapeutic agents MMAE and MMAF by fluorescence and
bioluminescence optical imaging (Figure 4A and B). The final in
vivo optical signals of tumors directly correlated with the ex vivo
tumor weights for all therapy groups (Table 2, Figure 5). These
results validate our triple reporter as an accurate and valuable tool
for imaging and quantifying in vivo tumor growth and response to
Figure 1. Comparison of four far-red and infrared fluorescent proteins. (A) The mean quartile (mean 25%) fluorescence intensities (FLI) of
E2-Crimson (C), infrared fluorescent protein (I), mNeptune (N), and mPlum (P) in HT-1080 cells measured by fluorescent-activated cell sorting (FACS)
were compared (100 mW laser with ex 568 nm and em 650–670 nm for C, N, and P; ex 690 nm and em 710–900 nm for I). (B) The top 5% brightest
HT-1080 cells from each fluorescent protein cell type were injected into athymic nude mice (16106 cells/injection; exposure time: 500 msec; ex 590/
23 nm and em 645LP for C, N, and P; ex 640/48 nm and em 700LP for I).
doi:10.1371/journal.pone.0097415.g001
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therapy. This is the first reported use of both fluorescence and
bioluminescence signals from a multi-reporter construct to
measure drug efficacy in vivo.
Currently, the standard method for measuring cancer growth
and regression in vivo is the use of calipers. One issue with caliper
measurements is that these measurements are typically used to
generalize the tumor volume from measurements in only two
dimensions with the equation [0.56 (largest diameter)6 (smallest
diameter)2] [18,19]. While tumors can sometimes be measured
with calipers in three dimensions for a more accurate estimate of
the tumor size [20], the orthotopic tumors in our study were often
too small, especially in the MMAE-treated group, to obtain an
accurate, consistent measurement of their heights through the
mammary fat pads. Additionally, while there was a strong
correlation between the caliper measurements and the fluores-
cence and bioluminescence signals, indicating that the fluores-
cence and bioluminescence signals are at least as good as the
standard methods for measuring tumors, caliper measurements
could not be attempted for tumors in the MMAE-treated group
after day 19. Even though calipers could not be used to detect
additional tumor shrinkage after day 19 in that treatment group,
the tumors were consistently detectable by fluorescence and
Figure 2. Triple reporter schematic and in vitro validation of components. (A) The optimized triple modality reporter construct consists of a
far-red fluorescent protein (E2-Crimson) for fluorescence imaging (FL), enhanced firefly luciferase enzyme (Luc2) for bioluminescence imaging (BL),
and truncated wild type herpes simplex virus I thymidine kinase (wttk) for positron emission tomography (PET). Viral 2A sequences (P2A and T2A)
separate each component. A flexible Gly-Ser-Gly linker (*) precedes each 2A sequence. (B) Epifluorescence microscopy of E2-Crimson (580/20 nm
excitation filter, 653/95 nm emission filter, 1 second exposure, 406oil objective) in the wild-type and triple reporter cell lines (stable expression .3
weeks). Images were scaled equally using ImageJ software. (C) Radiance photons (p/s/cm2/sr) produced from Luc2 activity in the triple reporter cell
lines (stable expression .3 weeks) compared to their respective wild type cell lines (7.46104 cells/well) immediately after exposure to D-luciferin
(150 mg/ml). The wells shown are representative of triplicate wells in a 48-well plate. (D) Wttk activity measured by cell death after 6 days of
ganciclovir treatment for the triple reporter cell lines (stable expression .3 weeks) compared to their respective wild type (WT) cell lines. Only viable
cells can convert the CellTiter 96 AQueous One Solution into a product with an absorbance at 490 nm, which was used to calculate the cell viability.
(E) Expression of each individual reporter protein in the triple reporter (CLW) cell lines compared to their respective wild type (WT) cell lines shown by
Western blot (36104 cells/well). Successful self-cleavage of viral 2A sequences was observed in all Western blots, as shown in the representative full
Western blot for Luc2. A fusion protein consisting of all three modalities (,135 kDa) or two of the successive modalities (,95 and ,106 kDa for E2-
Crimson+Luc2 and Luc2+wttk, respectively) was not observed.
doi:10.1371/journal.pone.0097415.g002
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bioluminescence. Thus, a major advantage of the triple reporter
system is that we can continue tracking and monitoring tumors
when they are too small to be assessed with calipers. Also, calipers
cannot be used to measure internal tumors in vivo, such as
orthotopic pancreatic and bladder tumors, making reporter
constructs essential for evaluating those models [21,22]. Further-
more, caliper measurements can be inconsistent or systematically
biased [23] because calipers are manually tightened and loosened
around the tumor to determine size, which is operator-dependent.
Finally, accurate caliper measurements require reliably palpable
tumors; thus, the first treatment evaluation often does not start
until the tumors are ,100 mm3 [19,24,25].
By using optical signals from our triple modality reporter, we
were able to sensitively track tumor growth and response to therapy
by fluorescence and bioluminescence from the pre-palpable stage
to large tumors up to 551 mm3 based on caliper measurements.
Figure 3. In vivo validation of the triple reporter components. Representative live animal images from the coronal plane of six MDA-MB-231
triple reporter tumors and two HT-1080 triple reporter tumors confirm the activity of all three imaging modalities in both cell lines in vivo. The
fluorescence signal is shown as the radiant efficiency (p/s/cm2/str)/(mW/cm2). The bioluminescence signal is shown as the radiance photons (p/s/cm2/
sr). The PET signal is shown as the% injected dose of 18F-FHBG per gram. High gut (GI) retention is characteristic of 18F-FHBG in microPET imaging,
which required that tumors be placed away from the abdomen of each mouse.
doi:10.1371/journal.pone.0097415.g003
Table 1. Sizes and modality signals of the triple reporter tumors after two weeks of growth.
MDA-MB-231 triple reporter tumor average (n=8) HT-1080 triple reporter tumor average (n=2)
Size measured by caliper (mm3) 96.2642.1 339.0663.6
Size measured by PET-CT (mm3) 118.0657.4 483.5652.3
Total fluorescence [(p/s)/(cm2/sr)] 3.6610861.46108 1.6610965.16108
Total bioluminescence (p/s) 3.0610861.86108 2.76101068.86109
Total PET (% bioavailable dose) 9.86102266.861022 1.76102165.961022
The tumor size, fluorescence signal, bioluminescence signal, and PET signal were quantified for the MDA-MB-231 and HT-1080 triple reporter tumors expressing all three
modalities in vivo. Only tumors that were healthy and large enough to be detectable by all three modalities of the triple reporter construct were averaged and included
in this dataset.
doi:10.1371/journal.pone.0097415.t001
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Optical signals allowed for unbiased quantification of tumor
therapy responses and for accurate tumor measurements in the
MMAE-treated group throughout the full therapy experiment
(Figure 4C). Additionally, the use of the triple reporter to monitor
treatment allows for earlier detection of treatment responses when
tumors have proportions more similar to those in human patients.
In summary, the engineering of cell lines expressing all three
modalities of our optimized triple reporter allowed for sensitive,
long-term quantification of tumor growth in vivo by fluorescence,
bioluminescence, and PET imaging. This triple reporter construct
has been optimized from previous designs [2–5] with the far-red
fluorescent protein E2-Crimson for fluorescent imaging in the far-
red part of the visible light spectrum; codon-optimized luciferase
Luc2 for bioluminescence with improved sensitivity; and truncated
wild type herpes simplex virus I thymidine kinase for PET
imaging. Of note is that although E2-Crimson proved the best of
the four candidate fluorescent proteins, its tetrameric structure
means that it is not ideal for fluorescence resonance energy
transfer or fusion to functional proteins. Additionally, short self-
cleaving viral 2A sequences separate each component of the three
reporter construct without requiring protein fusion or IRES
sequences [11]. With these spacers, detection limits for red
fluorescence required approximately 5-fold more cells than for
bioluminescence (Figure S1), but fluorescence correlated more
tightly than bioluminescence with tumor weight (Figure 5). The
results of the MMAE and MMAF therapy experiment validate the
use of the optimized triple modality reporter as an accurate and
quantifiable in vivo imaging tool. Applications of this triple reporter
to other tumor models could be useful for quantifying internal
tumor growth or tracking tumor metastasis.
Methods
Construction of the optimized triple modality reporter
and other control constructs
Individual cDNA encoding E2-Crimson (Clontech, Mountain
View, CA), Luc2 (Promega), and wttk (gift from Professor Sanjiv
Gambhir, Stanford University) were amplified using multiple
overlapping primers with graded concentrations, to incorporate
unique restriction sites, flexible Gly-Ser-Gly-linkers (GGGSGGG),
and 2A sequences (P2A: ATNFSLLKQAGDVEENPGP and
T2A: EGRGSLLTCGDVEENPGP) at the 59 and 39 ends in a
single round of PCR. Subsequent gene stitching via overlap
extension PCR yielded the following bicistronic cassettes adjoined
by a Gly-Ser-Gly-linker-2A sequence: NheI-E2-Crimson-BsiWI-
GSG-P2A-HindIII-Luc2-stop-BamHI and HindIII-Luc2-BamHI-
Figure 4. Quantification of the triple reporter optical signals to monitor therapy responses in vivo. (A) Average fluorescence signal [(p/s)/
(cm2/sr)] of each MDA-MB-231 triple reporter tumor treatment group over time. (B) Average bioluminescence signal (p/s) of each MDA-MB-231 triple
reporter tumor treatment group over time. (C) Average size (mm3) of each MDA-MB-231 triple reporter tumor treatment group over time based on
caliper measurements. MMAE or MMAF (0.5 nmol/g) was administered on days 7, 10, 13, 16, 19, and 22. Significant decreases (p,0.005) in the tumor
optical signals in the MMAE-treated group compared to the untreated and MMAF-treated groups are indicated by*.
doi:10.1371/journal.pone.0097415.g004
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GSG-T2A-XhoI-wttk-stop-XbaI. Amplified products were se-
quence verified before insertion into the pcDNA3.1/Hygro(+)
vector (Life Technologies, Grand Island, NY) using NheI/BamHI
or HindIII/XbaI, respectively. Finally, the Luc2-T2A-wttk-stop
fragment was subcloned into pcDNA3.1/Hygro(+)_E2-Crimson-
P2A-Luc2-stop plasmid using HindIII and XbaI restriction sites to
generate pcDNA3.1/Hygro(+)_E2-Crimson-P2A-Luc2-T2A-wttk.
The integrity of the tricistronic cassette and flanking restriction
sites were confirmed by sequence analysis in the final triple
modality reporter construct.
To generate other candidate triple modality reporters and
bicistronic expression control constructs, cDNA encoding IFP,
mNeptune (gift from Dr. Michael Z. Lin, Stanford University),
and mPlum were amplified with NheI and BsiWI at the 59 and 39
ends, respectively, and inserted in place of E2-Crimson in the
appropriate vectors via subcloning. E2-Crimson, IFP, mNeptune,
mPlum, Luc2, and wttk, each encoding a stop codon, were
subcloned into pcDNA3.1/Hygro(+) individually to make mono-
cistronic control vectors.
Comparison of the far-red and infrared fluorescent
proteins
E2-Crimson, IFP, mNeptune, and mPlum, all inserted into the
pcDNA3.1/Hygro(+) backbone, were transfected into HT-1080
Figure 5. Correlation between triple reporter tumor optical signals in vivo and weights ex vivo following therapy. (A) Fluorescence
signal [(p/s)/(cm2/sr)] vs. bioluminescence signal (p/s) of the MDA-MB-231 triple reporter tumors on day 28 of tumor growth. (B) Fluorescence signal
[(p/s)/(cm2/sr)] vs. weight (mg) of the MDA-MB-231 triple reporter tumors on day 28 of tumor growth. (C) Bioluminescence signal (p/s) vs. weight (mg)
of the MDA-MB-231 triple reporter tumors on day 28 of tumor growth.
doi:10.1371/journal.pone.0097415.g005
Table 2. Final triple reporter tumor optical signals in vivo and weights ex vivo following therapy.
Untreated average (n=10) MMAF average (n =10) MMAE average (n=10)
Weight (mg) 885.96416.2 878.36536.7 29.8621.4*
Total fluorescence [(p/s)/(cm2/sr)] 8.5610863.46108 8.4610864.16108 2.6610763.36107*
Total bioluminescence (p/s) 1.4610968.96108 1.3610969.86108 2.8610762.16107*
Caliper-estimated size (mm3) 393.76237.8 413.46245.7 Sub-palpable*
Tumors from the therapy experiment were imaged then resected and weighed after 28 days of growth in vivo. Optical signals of the triple reporter tumors were
representative of the tumor mass. Tumors in the MMAE-treated group were too small to be measured by a caliper after day 19. Significant decreases (p,0.005) in the
tumor weight and optical signals in the MMAE-treated group compared to the untreated and MMAF-treated groups are indicated by*.
doi:10.1371/journal.pone.0097415.t002
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cells (American Type Culture Collection, ATCC) with Lipofecta-
mine2000 (Life Technologies) and selected for stable fluorescent
protein expression with 3 weeks of hygromycin B (Sigma)
treatment (from 50–500 mg/ml, dose increased every 3 days). A
FACS Vantage SE Diva (BD Biosciences) was used to assess the
population fluorescence with a 568 nm laser and 660/20 nm
emission filter (E2-Crimson, mNeptune, and mPlum) and a
690 nm laser and 710–900 nm emission filter (IFP) at 100 mW
power. The 5% brightest cells (16106) were subcutaneously
implanted into athymic nude mice (female, 6-weeks-old), and the
tumors were imaged 3 days later at ex 590/23 nm and em 645LP
(E2-Crimson, mNeptune, and mPlum) or ex 640/48 nm and
em700 LP (IFP) in a Maestro imager (CRi).
This study was carried out in accordance with the Guide for the
Care and Use of Laboratory Animals of the National Institutes of
Health recommendations. The UCSD Institutional Animal Care
and Use Committee approved of all animal studies (Protocol:
S04011). All imaging and injections were performed under
isoflurane anesthesia.
Comparison of triple reporter fluorescence and
bioluminescence sensitivity
The triple reporter cDNA was transfected into HT-1080 cells
(ATCC) with Lipofectamine2000 and selected for stable fluores-
cent protein expression as described in the previous section. A
FACS Vantage SE Diva was used to collect the 5% brightest cells
(100 mW laser with ex 568 nm and em 660/20 nm).
Athymic nude mice (female, 6-weeks-old) were implanted with
subcutaneous HT-1080 triple reporter tumors (500–5000 cells/
tumor in matrigel). Whole body fluorescence and bioluminescence
was imaged using an IVIS Spectrum (Caliper Life Sciences)
starting 5 minutes after tumor cell implantation. Mice were
anesthetized with 2.5% isoflurane in 100% oxygen carrier gas.
Fluorescence background signal was imaged with a 465 nm
excitation filter and a 660 nm emission filter (FOV: D; binning:
medium; f stop: 2; and exposure time: 1 second). E2-Crimson
fluorescence signal was imaged with a 605 nm excitation filter and
a 660 nm emission filter (FOV: D; binning: medium; f stop: 2; and
exposure time: auto). Fluorescence background signal was
subtracted from E2-Crimson fluorescence signal. Bioluminescence
background was imaged with the excitation filter blocked and
emission filter open (FOV: D; binning: medium; f stop: 1; and
exposure time: 1 second). Then, mice were injected subcutane-
ously on the flank with 150 mg of D-luciferin in PBS (phosphate
buffered saline) per kg of mouse. Mice were imaged 15 minutes
after injection with the excitation filter blocked and emission filter
open (FOV: D; binning: medium; f stop: 1; and exposure time:
auto).
Lentiviral cloning and production
The lentiviral vector plasmid, packaging psPAX2 plasmid, and
pMDG.2 plasmid for VSV-G (vesicular stomatitis virus G)
glycoprotein expression were generous gifts from Professor Didier
Trono (Ecole Polytechnique Fe´de´rale de Lausanne). The triple
reporter cDNA was subcloned into the lentiviral vector plasmid
with PCR amplification and standard cloning techniques. The
transgene was inserted between a CMV promoter and WPRE
(woodchuck hepatitis virus posttranscriptional regulatory element)
sequence.
The HEK293A cell line (Life Technologies) was grown to 85%
confluence in 15 cm culture dishes in high glucose DMEM media
(Corning) supplemented with 10% fetal bovine serum and 1%
penicillin/streptomycin (Corning) at 37uC in a 5% CO2 incubator.
Before HEK293A transfection, the media in the culture was
replaced with viral production media (high glucose DMEMmedia,
5 mM sodium butyrate, and 1% penicillin/streptomycin). The
triple reporter lentiviral plasmid (24 mg), psPAX2 plasmid (45 mg),
and pMDG.2 plasmid (30 mg) were added to 6 ml of Opti-MEM
media (Life Technologies). Another 6 ml of Opti-MEM media
containing polyethylenimine (0.5 mM; Sigma-Aldrich) was added
to the 6 ml of Opti-MEM media containing the plasmids, and the
mixture was incubated at room temperature for 15 minutes. An
aliquot of this final solution (2 ml) was added to each dish. After
10 hours, media from each dish was replaced with fresh viral
production media. The virus-containing media was collected at 48
and 72 hours after transfection and pooled for subsequent
purification and concentration steps.
The pooled virus-containing media was filtered through a
0.45 mm filter (Millipore). The media was placed on top of a
sucrose layer (20% sucrose in PBS) in centrifuge tubes and
centrifuged in a SW28 rotor (Beckman Coulter) at 25,000 rpm
(82,700 g) and 4uC for 2 hours. Each lentivirus pellet
was resuspended in 40 ml of PBS for immediate use or stored at
280uC.
Lentiviral transduction and FACS of the triple reporter
cancer cell lines
MDA-MB-231 and HT-1080 cancer cells (ATCC) were grown
to 85% confluence in 25 cm2 tissue culture flasks in complete
growth media (EMEM media [ATCC], 10% fetal bovine serum,
and 1% penicillin/streptomycin) at 37uC in a 5% CO2 incubator.
Media from each flask was replaced with 5 ml of high glucose
DMEM media supplemented with 5 mM sodium butyrate,
0.1 mM PEI, and 40 ml of the triple reporter lentivirus. After
12 hours, the viral media was replaced with complete growth
media, and the cell lines were expanded in culture for 3 weeks. A
FACS Vantage SE Diva was used to collect the top 1.5% brightest
cells from each cell line based on E2-Crimson fluorescence. The
MDA-MB-231 and HT-1080 FACS populations were expanded
in culture for 3 weeks before use in all subsequent experiments.
In vitro E2-Crimson, Luc2, and wttk activity
Cells were imaged for E2-Crimson expression with an
epifluorescence microscope (Zeiss) using ex 580/20 nm, em
653/95 nm, and a 406 oil objective with a 1 second exposure
time.
To confirm Luc2 activity, 7.46104 cells were grown in each well
of a 48-well tissue culture plate with complete growth media for
24 hours. Media was replaced with 100 ml of PBS, and D-luciferin
(In Vivo Imaging Solutions) was added immediately before
imaging at a final working concentration of 150 mg/ml. The plate
was imaged with an IVIS Spectrum (FOV: C; binning: medium; f
stop: 1; and exposure time: auto). Each cell line was tested in
triplicate.
Wttk activity was confirmed by ganciclovir treatment. Cells
(46103) were grown in each well of a 96-well tissue culture plate
with complete growth media supplemented with either 0 mg/ml,
1 mg/ml, or 10 mg/ml ganciclovir (InvivoGen) for 6 days. Cells
were observed with bright field microscopy to visually assess cell
death by ganciclovir treatment. Cell death from ganciclovir
treatment was then quantified using the CellTiter 96 AQueous
One Solution Cell Proliferation Assay (Promega). Results of this
colorimetric method for determining the live cell count were
collected using an Infinite M1000 PRO plate reader (Tecan)
measuring absorbance at 490 nm in the bottom read mode. The
cell viability was then calculated by comparing the absorbance
readings from the ganciclovir treatment with the untreated cells.
Each cell line was tested in triplicate.
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Western blot analysis
Cells (1.56103) from each cell line were lysed in RIPA buffer
(Cell Signaling Technology) with 0.5% SDS and complete
protease inhibitors (Roche) by mechanical disruption and freeze
thawing; the cell mixtures were then reduced and denatured in
NuPage LDS Sample Buffer (Life Technologies) with 8%
b-mercaptoethanol, at 95uC for 5 minutes. The samples were
run next to the Precision Plus Duel Color Standards (Bio-Rad) in a
4–12% Bis-Tris polyacrylamide gel (Life Technologies). Expres-
sion of each reporter protein and self-cleavage of the viral 2A
sequences were evaluated by Western blots with a DsRed rabbit
polyclonal antibody (Clonetech) diluted 1:3000, firefly luciferase
mouse monoclonal antibody (Abcam) diluted 1:3000, HSV-1
thymidine kinase goat polyclonal antibody (Santa Cruz Biotech-
nology) diluted 1:250, and GAPDH rabbit polyclonal antibody
(Sigma-Aldrich) diluted 1:5000. Secondary antibodies used were a
goat anti-rabbit IgG HRP conjugate diluted 1:3000 (Cell Signaling
Technologies), goat anti-mouse IgG HRP conjugate diluted
1:3000 (Bio-Rad), and donkey anti-goat IgG HRP conjugate
diluted 1:2500 (Promega).
In vivo optical imaging of the triple reporter
Athymic nude mice (female, 6-weeks-old) were implanted with
bilateral tumors, orthotopically into the mammary fat pads with
the MDA-MB-231 triple reporter cells (16106 cells/tumor in
matrigel) or subcutaneously at the shoulder blades with the HT-
1080 triple reporter cells (56105 cells/tumor in PBS). These
locations were chosen to separate the non-specific 18F-FHBG
signal detected within the intestinal tract in the abdomen. The
tumors were grown for 2 weeks.
Whole body fluorescence and bioluminescence was imaged
using an IVIS Spectrum, as described in the comparison of triple
reporter fluorescence and bioluminescence sensitivity section. The
total radiant efficiency (p/s)/(cm2/sr) and total radiance photons
(p/s) were quantified by drawing ROIs over the tumor using
Living Image software (Caliper Life Sciences).
In vivo PET imaging of the triple reporter
The David Stout laboratory in the Crump Institute for
Molecular Imaging at Univeristy of California, Los Angeles
synthesized 9-(4-[18F]Fluoro-3-hydroxymethylbutyl)guanine (18F-
FHBG) and directed all microPET experiments [26,27].
Mice were warmed for 20 minutes prior to tail vein injection of
,150 uCi of 18F-FHBG. After 2 hours for specific uptake and
non-specific clearance, mice were anesthetized using 2% isoflurane
in 100% oxygen carrier gas and heat supported throughout the
entire imaging process. Mice were imaged using a multimodality
chamber designed to maintain anesthesia, heating, and reproduc-
ible positioning during all scans.
PET scans were acquired for 10 minutes using an Inveon DPET
system (Siemens Preclinical Solutions). Images were reconstructed
using filtered backprojection to a resolution of ,1.8 mm. Images
were reconstructed without attenuation or scatter correction
because these effects are fairly small in mice and not necessary
for this experiment. CT images were acquired immediately after
PET scans using a MicroCAT II small animal CT system (Siemens
Preclinical Solutions). The exposure settings were 70 kVp,
500 mAs, 500 ms exposure time, and 360u rotation in 1u steps
with 2.0 mm aluminum filtration. Images were reconstructed
using a modified Feldkamp process to a cubic voxel size of
0.20 mm. PET and CT images were automatically coregistered
and stored in a single file.
Wttk activity was quantified by the% injected dose of 18F-
FHBG uptake in tumors. Volumetric ROIs were drawn around
the tumors as well as the whole body regions of the mice using
AMIDE software [28]. Volumetric ROIs measured 18F-FHBG
uptake as well as the size in mm3. The% injected dose was
calculated by dividing the tumor 18F-FHBG uptake by the whole
body 18F-FHBG uptake. The% injected dose per mm3 of the wild
type (untransduced) tumors was subtracted from the% injected
dose per mm3 of the triple reporter tumors to remove the
background PET-CT signal.
The UCLA Institutional Animal Care and Use Committee
approved of all animal studies (Protocol: 2006–135).
Quantifying the therapeutic response of triple reporter
tumors in vivo and ex vivo
Athymic nude mice (female, 5-weeks-old) were implanted with
bilateral MDA-MB-231 triple reporter tumors (7.56105 cells/
tumor in matrigel) orthotopically in the mammary fat pads. After 7
days, mice were randomized into 3 treatment groups (untreated,
MMAE-treated, and MMAF-treated) with 5 mice per group for a
total of 10 tumors per group. Mice were administered 0.5 nmol
drug per gram mouse every 3 days for 6 doses on days 7, 10, 13,
16, 19, and 22. Whole body fluorescence and bioluminescence
images were captured with an IVIS Spectrum and quantified using
Living Image software, as described earlier. The total fluorescence
and bioluminescence signals of the tumors were averaged within
each group. The tumor size was also measured using millimeter
calipers (the largest diameter and smallest diameter were
measured; the tumor size was estimated as 0.56[largest diameter]
6 [smallest diameter]2) starting on day 16, which is when the
tumors in the untreated and MMAF-treated groups were reliably
palpable. The mouse weight was recorded throughout the
experiment. The tumors were resected and weighed 4 weeks post
implantation. The tumor weights were averaged for each group
for comparison with the final in vivo average fluorescence and
bioluminescence signals.
Statistical analyses
Statistical analyses were conducted with a 2-way ANOVA
(analysis of variance) with multiple comparisons after the data
were log-transformed. All results are given as the mean6 standard
deviation. P,0.005 was considered statistically significant.
Ethics statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Committee on the Ethics of Animal
Experiments of the University of California San Diego (Protocol
Number: S04011) and the Committee on the Ethics of Animal
Experiments of the University of California Los Angeles (Protocol
Number: 2006-135). All imaging and injections were performed
under isofluorane anesthesia, and all efforts were made to
minimize suffering.
Accession code
The triple modality reporter GenBank accession number is
KJ561464.
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Supporting Information
Figure S1 Comparison of fluorescence and biolumines-
cence sensitivity. (A) Fluorescence and bioluminescence
imaging of varying numbers of cells from HT-1080 cells expressing
the triple reporter; bioluminescence could detect 500 cells while
fluorescence required 2,500 cells for detection. (B) Confirmation of
the bioluminescence sensitivity for as few as 500 cells in another
athymic nude mouse with HT-1080 triple reporter cells. (a1–a6)
represent 5,000 cells; (b1–3) are 2,500 cells; (c1–c3) are 1,000 cells;
and (d1–d3) are 500 cells injected subcutaneously. Gut autofluo-
rescence from the alphalpha chow is indicated by *. The
fluorescence signal is shown as the radiant efficiency (p/s/cm2/
str)/(mW/cm2). The bioluminescence signal is shown as the
radiance photons (p/s/cm2/sr).
(TIF)
Table S1 Sizes and optical signals for the HT-1080
triple reporter tumors not detectable by PET. Five smaller
HT-1080 tumors were not detectable by PET, but they still
produced reliable fluorescence and bioluminescence signals.
(TIF)
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